Free Trial

Novavax (NVAX) Stock Price, News & Analysis

Novavax logo
$8.37 -0.41 (-4.67%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$8.38 +0.01 (+0.06%)
As of 08/8/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Novavax Stock (NASDAQ:NVAX)

Key Stats

Today's Range
$8.28
$9.13
50-Day Range
$6.30
$8.78
52-Week Range
$5.01
$15.22
Volume
9.97 million shs
Average Volume
7.09 million shs
Market Capitalization
$1.36 billion
P/E Ratio
3.67
Dividend Yield
N/A
Price Target
$15.86
Consensus Rating
Hold

Company Overview

Novavax Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

NVAX MarketRank™: 

Novavax scored higher than 94% of companies evaluated by MarketBeat, and ranked 60th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Novavax has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 4 buy ratings, 2 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Novavax has only been the subject of 3 research reports in the past 90 days.

  • Read more about Novavax's stock forecast and price target.
  • Earnings Growth

    Earnings for Novavax are expected to grow in the coming year, from ($1.46) to $0.08 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Novavax is 3.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.09.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Novavax is 3.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.77.

  • Price to Earnings Growth Ratio

    Novavax has a PEG Ratio of 0.10. PEG Ratios below 1 indicate that a company could be undervalued.

  • Percentage of Shares Shorted

    26.52% of the outstanding shares of Novavax have been sold short.
  • Short Interest Ratio / Days to Cover

    Novavax has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Novavax has recently decreased by 7.47%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Novavax does not currently pay a dividend.

  • Dividend Growth

    Novavax does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    26.52% of the outstanding shares of Novavax have been sold short.
  • Short Interest Ratio / Days to Cover

    Novavax has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Novavax has recently decreased by 7.47%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Novavax has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 33 news articles for Novavax this week, compared to 11 articles on an average week.
  • Search Interest

    39 people have searched for NVAX on MarketBeat in the last 30 days. This is an increase of 105% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Novavax to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Novavax insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.00% of the stock of Novavax is held by insiders.

  • Percentage Held by Institutions

    53.04% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Novavax's insider trading history.
Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Stock News Headlines

Novavax Stock Surges Amid Strategic Gains
Americans are rushing into gold (but not billionaires!)
Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scrambling to buy gold coins and bars. But some savvy investors have used a different way to profit from gold bull runs — a special investment with a long history of making 13 times … 21 times … 157 times … even a surprising 1,000 times more than physical gold.
Brokerages Set Novavax, Inc. (NASDAQ:NVAX) PT at $15.86
TD Cowen Reaffirms Their Hold Rating on Novavax (NVAX)
Novavax (NASDAQ:NVAX) Trading 14.6% Higher Following Strong Earnings
Novavax (NASDAQ:NVAX) Shares Gap Up on Earnings Beat
See More Headlines

NVAX Stock Analysis - Frequently Asked Questions

Novavax's stock was trading at $8.04 on January 1st, 2025. Since then, NVAX stock has increased by 4.1% and is now trading at $8.37.

Novavax, Inc. (NASDAQ:NVAX) issued its quarterly earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.69. The business's revenue was down 42.4% compared to the same quarter last year.
Read the conference call transcript
.

Novavax shares reverse split on Friday, May 10th 2019.The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional investors of Novavax include Shah Capital Management (7.11%), Geode Capital Management LLC (2.33%), SG Americas Securities LLC (0.56%) and Jupiter Asset Management Ltd. (0.54%). Insiders that own company stock include James F Young, Filip Dubovsky, Rachel K King and Gregory M Glenn.
View institutional ownership trends
.

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novavax investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Moderna (MRNA), Advanced Micro Devices (AMD), Pfizer (PFE) and Alibaba Group (BABA).

Company Calendar

Last Earnings
8/06/2025
Today
8/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NVAX
CIK
1000694
Employees
1,990
Year Founded
1987

Price Target and Rating

High Price Target
$26.00
Low Price Target
$6.00
Potential Upside/Downside
+89.5%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.28
Trailing P/E Ratio
3.67
Forward P/E Ratio
N/A
P/E Growth
0.1
Net Income
-$187.50 million
Net Margins
39.20%
Pretax Margin
39.99%
Return on Equity
-142.33%
Return on Assets
28.65%

Debt

Debt-to-Equity Ratio
5.93
Current Ratio
2.36
Quick Ratio
2.03

Sales & Book Value

Annual Sales
$682.16 million
Price / Sales
1.99
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.23 per share
Price / Book
36.39

Miscellaneous

Outstanding Shares
162,420,000
Free Float
160,798,000
Market Cap
$1.36 billion
Optionable
Optionable
Beta
2.50

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:NVAX) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners